Introduction
============

Prescription medicines have become a major component of health systems worldwide. Per capita pharmaceutical expenditures in 2005/2006 ranged from US\$ 7.61 in low-income countries to US\$ 431.6 in high-income countries, with considerable variation between income groups in each country ([@R1]). On average, the use of pharmaceuticals in hospitals and other health care facilities raises the pharmaceutical bill by around 20% ([@R2]). The rise in pharmaceutical expenditure is the result of the amalgamated effect of several factors including national and international pharmaceutical regulations, pricing policies, the influence of pharmaceutical companies, innovation of new drug delivery systems, the emergence of new pharmaceuticals for the treatment of previously untreated conditions and the prescribers\' decision ([@R3]--[@R5]).

Physicians are the primary decision makers on healthcare resources. Physicians\' prescribing decisions are the key for hospitals dominance over the health sector market players; pharmaceutical companies\' market share; and payers target to curb costs ([@R6],[@R7]). The variation in physician practice explains the difference in expenditure in the health sector ([@R8],[@R9]). Patient outcome also varies with practice variations ([@R9],[@R10]). The physician practice variation has a pronounced effect on healthcare spending increment. However, the connection between healthcare spending and outcomes is loose ([@R4],[@R6]).The physicians\' practice significantly varies in medicine prescribing and laboratory procedures ordering ([@R11],[@R12]).

The prescribing decision is the result of a multitude of intertwined factors such as the educational background of prescribers, the working environment and so on ([@R13]--[@R15]). Factors influencing prescribers\' decisions are the most important input to develop practice guidelines, healthcare policy and to devise a regulation for the pharmaceutical market. In addition, the pivotal-position of physicians makes the study of factors which influence prescribing decision of tremendous worth. Therefore, highlighting factors influencing prescribing decision helps to devise a structured way to rationalize patient care process and healthcare expenditure.The aim of this review was to identify the factors affecting prescribing decision of physicians.

Methods
=======

**Search strategy**: Electronic databases (PubMed/MEDLINE CENTRAL, Scopus, Cochrane Libraries and Google scholar) were searched from 2000 to 2016. The search was done by combining the following keywords with Boolean operators "AND" and "OR": Prescribing, Prescription, factor, determinant, behavior, practice, preferences, inappropriate, optimal, pattern, decisions and suggest. Searching in each database was adapted to databases characteristics, and additionally Medical Subject Headings (MeSH) were considered for PubMed.

**Eligibility criteria**: The major selection criteria were: (1) factors influencing prescribing decision should be the main objective, (2) studies should be original articles, (3) the full text should be available and provide enough information, (4) the studies should be written in English, and (5) published from 2000 to 2016.

**Selection of articles**: The titles and abstracts of all records were screened by one reviewer. Then, the full texts were selected based on the inclusion criteria by two reviewers, independently. Discrepancies were settled by discussion and consensus including a third reviewer.

**Data abstraction process**: Two reviewers, using standardized format, separately extracted the following information: authors\' name, date of publication, study design, aim of the study, physician\'s specialty, type of medicines, and identified factors.

**Validity of selected articles**: The heterogeneity of the reviewed studies hampers the use of the validated tools for quality assessment. Nevertheless, the full texts were appraised based on the following criteria, and disagreements were solved by discussion: Did the study have sound objective?Did the study mentioned factors influencing prescribing decision clearly?Did the study clearly describe the setting and data sources?Did the study use reliable methods?Did the study discuss the validity and the limitations of the results?

**Data synthesis**: The recognized factors affecting prescribing decision were organized in a table.

Results
=======

**Selection and characteristics of the studies**: The search strategy identified 1122 records, and 36 articles were finally selected ([Figure 1](#F1){ref-type="fig"}).

![Bibliographical searches and inclusion process](EJHS2806-0795Fig1){#F1}

**Validity of selected studies**: All the included articles had clear objectives, mentioned factors influencing prescribing decision clearly, and described the setting and data sources. Five studies used small samples (11 to 32 study participants) ([@R16]--[@R20]). Eleven studies did not describe the generalizability and limitation of their findings ([@R16],[@R18],[@R21]--[@R29]).

**Factors influencing prescribing decision**: A total of 33 factors were identified. Physicians\' personal attributes, cost of treatment, pharmaceutical industries\' and patients\' preferences were the most frequently identified factors to influence prescribing decisions ([Table 1](#T1){ref-type="table"}).

###### 

Factors influencing prescribing decision of physicians

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Serial\   Identified factor                                          Articles                                                                                    Frequency
  No                                                                                                                                                               
  --------- ---------------------------------------------------------- ------------------------------------------------------------------------------------------- -----------
  1\.       Personal attributes[\*\*](#TF2){ref-type="table-fn"}       ([@R19], [@R23], [@R26], [@R29]--[@R32], [@R35], [@R38], [@R39], [@R41], [@R46], [@R48],\   15
                                                                       [@R49], [@R51])                                                                             

  2\.       cost of treatment                                          ([@R20], [@R26], [@R28]--[@R30], [@R34], [@R36]--[@R39], [@R42], [@R44], [@R48])            13

  3\.       Patient preference                                         ([@R20], [@R23], [@R25], [@R26], [@R28], [@R30], [@R32], [@R36], [@R37], [@R39], [@R44],\   12
                                                                       [@R48])                                                                                     

  4\.       Pharmaceutical industries                                  ([@R20], [@R26], [@R28], [@R31], [@R36], [@R38], [@R39], [@R42], [@R44], [@R47], [@R48])    11

  5\.       Head of the departments and colleagues                     ([@R20], [@R23], [@R27], [@R30], [@R31], [@R39], [@R47], [@R51])                            8

  6\.       patient\'s or families expectation                         ([@R18], [@R19], [@R23], [@R33], [@R38], [@R47], [@R50], [@R51])                            8

  7\.       Patient\'s clinical condition                              ([@R23], [@R26], [@R34], [@R35], [@R41], [@R43], [@R50])                                    7

  8\.       Clinical effectiveness and safety of the drug              ([@R25], [@R28], [@R29], [@R34], [@R36], [@R39], [@R48])                                    7

  9\.       Practice guidelines and policies                           ([@R19], [@R21], [@R23], [@R29], [@R32], [@R42], [@R48])                                    7

  10\.      Patients insurance coverage                                ([@R17], [@R35], [@R36], [@R39], [@R47], [@R51])                                            6

  11\.      Willingness to involve patients in decisionmaking          ([@R19], [@R23], [@R31], [@R46], [@R47], [@R50])                                            6

  12\.      Drug\'s indication                                         ([@R26], [@R33], [@R34], [@R42], [@R47])                                                    5

  13\.      Available resources and practice location                  ([@R23], [@R28], [@R39], [@R51])                                                            4

  14\.      Pharmaceutical attributes[\*](#TF1){ref-type="table-fn"}   ([@R28], [@R36], [@R47], [@R51])                                                            4

  15\.      Preferred Information sources                              ([@R26], [@R28], [@R31], [@R36])                                                            4

  16\.      Socio-demography of patients                               ([@R27], [@R49], [@R51])                                                                    4

  17\.      Diagnostic procedures                                      ([@R21], [@R23], [@R47])                                                                    3

  18\.      Financial incentives                                       ([@R21], [@R39], [@R41])                                                                    3

  19\.      Patients ease of access to drug therapy                    ([@R19], [@R21], [@R43])                                                                    3

  20\.      Time constraint                                            ([@R20], [@R32], [@R43])                                                                    3

  21\.      Resistance and treatment failure                           ([@R21], [@R26])                                                                            2

  22\.      Patients past experience with medication                   ([@R25], [@R48])                                                                            2

  23\.      Higher ratio of specialists to general physicians          ([@R27], [@R39])                                                                            2

  24\.      Political and administrative influence                     ([@R23], [@R39])                                                                            2

  25\.      Patient knowledge                                          ([@R27], [@R33])                                                                            2

  26\.      Patient\'s ability to take the drug                        ([@R42], [@R47])                                                                            2

  27\.      Clinicians\' professionals ethos                           ([@R19])                                                                                    1

  28\.      Number of doctors or doctor per patient                    ([@R41])                                                                                    1

  29\.      Physicians general attitudes towards the health\           ([@R46])                                                                                    1
            system                                                                                                                                                 

  30\.      Preference for local company                               ([@R26])                                                                                    1

  31\.      Curiosity about the drug                                   ([@R26])                                                                                    1

  32\.      Personal 'head-held' drug formulary                        ([@R20])                                                                                    1

  33\.      participation in clinical trial                            ([@R39])                                                                                    1
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

the dose, frequency, rout of administration and monitoring requirement of the drug

experience, specialty, continuous professional development and area of interest of physician

Discussion
==========

This was a review on the factors influencing prescribing decisions of physicians. Prescribers take the lion\'s share in rational pharmaceutical use. Prescribers decide the indication of the medicine based on the patients\' condition. The clinical condition of the patient including the sign and symptoms, co-morbid conditions and uncertain diagnosis are some of the points looked by prescribers before prescribing ([@R17],[@R20],[@R26],[@R31],[@R35],[@R36],[@R44]). A change in prescribing decision may also happen when physicians become in a difficult condition to identify the clinical indication of medicines or face a fear of complications ([@R52],[@R53]). Incomplete clinical pictures influence prescribers to change their prescribing decision ([@R54]). The clinical effectiveness and safety of pharmaceuticals are often considered to achieve the goal of therapy and enhance the patient compliance. Previous exposure of prescribers to the medicine and its past clinical success has a big role in altering prescribing decision ([@R16],[@R23],[@R25],[@R34],[@R41],[@R50]). It was shown that the use of diagnostic procedures for identification of the clinical condition and valid clinical guidelines fosters the rational prescribing effectively ([@R19],[@R20],[@R25], [@R32],[@R37]).

A number of factors associated with the working and external environment that influence prescribing decision were highlighted in this review. It is a well-established fact that learning organizations and organizational structures increase the performance of employees ([@R55]). Availability of diagnostic and pharmaceutical resources in the organization could also influence the prescribing decision of physicians ([@R27],[@R34],[@R35],[@R48],[@R50]). Pharmaceutical companies try to influence the prescribing decision of prescribers by creating a mutual benefit based relationship ([@R39]). The pharmaceutical companies need the relationship to show how differentiated their products are and to increase their market share. Pharmaceutical companies usually do face-to-face detailing, provide medicine samples, provide written evidence, organize meetings, organize medicine launches, sponsor continuous medical education and provide gifts ([@R5],[@R15],[@R56],[@R57]). The type of advertising and promotion strategies is dynamic based on the physicians\' reactions ([@R58]).

Clinical guideline development needs considerable heedfulness. Clinical guidelines that limit the discretion of prescribers will have doubtful implementation. It was revealed that physicians\' involvement in hospital decision making process and development of hospital specific guidelines influence their prescribing decision ([@R37]). Physicians adhere more to the guidelines which their reflection was considered ([@R32]). Furthermore, feedback on the prescribing behavior based on agreed and reflected criteria improves the prescribing behavior more than mere distribution of guidelines ([@R32],[@R59],[@R60]).

The physicians\' attributes which include the clinical experience, specialty, continuous professional development and practice decision was the most frequently mentioned prescriber related factor. Clinical experience outlined as a factor to influence prescribing decision by most of the reviewed articles ([@R16],[@R18],[@R26],[@R33],[@R43],[@R44],[@R47]). The exposure of physicians for different class of medicines and patient outcome are expected to increase with increased clinical experience and years of service. Hoever, a single study claimed that the quality of care decrease with increased clinical experience ([@R61]). Experience leads to a personal, informal medicine list, which may conflict with new guidelines ([@R22]). Specialist physicians\' influence on prescribing decisions is expected to be high. Especially, in new medicine prescribing, most of the general practitioners are dependent on what was said by specialists ([@R62]). Physicians\' perceptions of patient expectation influence their prescribing behavior ([@R17]), which is a stronger predictor of prescribing than patient perception([@R63]). Physicians prescribe not to risk their relationship with patients when they perceive prescription is required ([@R64]). The information sources used by physicians have an important role in altering their prescribing decisions ([@R16],[@R41],[@R43],[@R44],[@R50]). Although medical reference books and scientific literatures have a large theoretical importance, colleagues, clinical meetings and medical representatives are key sources of information used to prescribe new medicines ([@R65]). Information from pharmaceutical companies increases awareness on available medicines in the market. However, this information may turn physicians to high prescribers, high cost prescribers and low prescribing quality practitioners ([@R66]). Physicians\' interest in a particular area and involvement in clinical trial are also important factors for new medicine prescribing ([@R67]).

In the current review a number of factors associated with the patient or the care givers were identified: the socio-demographic status, knowledge of patient about medicines, expectation and request to a particular treatment. The patient socio-demographics such as age, sex, social status has to be considered for better quality of care([@R23],[@R27],[@R36],[@R47]). The knowledge of the patient on pharmaceutical products makes the patient request for a specific medication and alters patient expectations ([@R17],[@R23],[@R68]). Generally, patients who expect prescription are more likely to have it([@R69],[@R70]). Patient\'s pressure on physicians may lead to unnecessary prescribing and referral([@R63]); but, the transition from the old paternalistic care to engagement of patients in decision making has increased the role of patients as an actor in decision making ([@R71]). Some studies showed that the involvement of patients in their care selection made physicians to change prescribing decision([@R69],[@R70]). Likewise, selfmedication practice towards antibiotics has made physicians to let the patient continue the unnecessary antibiotics to prevent resistance or to change the regimen to the more potent medicine due to the perception of resistance([@R19],[@R45]).

The other factors identified are associated with the economic conditions: cost, insurance and financial incentives. The cost of a medicine to a patient is usually considered by physicians during prescribing ([@R16],[@R21],[@R22],[@R26],[@R31],[@R34],[@R35],[@R41],[@R44],[@R48],[@R50]). Insurance, in general, was found to influence the selection of type and quantity of health care utilization and also improve health ([@R72]). The level of reimbursement of pharmaceuticals affects the prescribing decision of physicians. Insured patients consume more health care service than uninsured patients with a lower expenditure ([@R73]). The financial incentives for the prescriber are motives that influence the prescribing behavior and could increase induced demand ([@R19]). Financial incentives can be given by lower copayments for patients who choose medicines preferred by the payer ([@R74]). Financial incentives can also be achieved by physician payment modalities and health care financing systems. Capitation payment for each patient registered had shown a reduction in prescription costs ([@R75]).

Our findings showed that many factors can influence the prescribing decisions of physicians. These factors can be used in policy development to enhance the prescribing decision of prescribers. Factors may or may not give chance for change. Demographic characteristics and socioeconomic factors give a little room for improvement ([@R56],[@R76]). However, factors like knowledge, educational level, experience, the number of practicing professionals, cost sharing and guidelines can be modified to influence prescribing behavior.

The review included only articles published in the English language which might introduce bias. The studies included in the review had a different study design, data collection, analysis technique and many of them were done with a few classes of medicines. The factors level of influence on the prescribing decision was not included in this review.

Physician\'s personal attributes, cost of the medicine, and pharmaceutical industries\' marketing and promotion strategies were mostly mentioned to influence prescribing decision. The identified factors showed prescribing is not only geared for patient benefit, but also towards physician\'s interest. The use of valid and reliable practice guidelines could reduce the negative impact of wide ranges of factors and promote the rational prescribing effectively. Studies on causative relationship between identified factors and prescribing decision may be a very effective research area for further studies.
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